Wedbush Reiterates Outperform on Climb Bio, Maintains $17 Price Target

Benzinga Newsdesk www.benzinga.com Negative 77.2%

Neg 77.2% Neu 0% Pos 0%

Wedbush analyst Laura Chico reiterates Climb Bio (NASDAQ:CLYM) with a Outperform and maintains $17 price target.

Comments

No comments yet. Be the first!